Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06498960Not ApplicableRecruiting

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Role: lead

NCT04758611Not ApplicableActive Not Recruiting

The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt)

Role: lead

NCT05250505Not ApplicableActive Not Recruiting

Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Role: lead

NCT05232838Not ApplicableActive Not Recruiting

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Role: lead

NCT05501002Not ApplicableTerminated

Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus

Role: lead

All 5 trials loaded